nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—UGT1A1—lung cancer	0.387	0.81	CbGaD
Naltrexone—ABCB1—lung cancer	0.0906	0.19	CbGaD
Naltrexone—UGT1A1—Erlotinib—lung cancer	0.0633	0.188	CbGbCtD
Naltrexone—UGT1A1—Irinotecan—lung cancer	0.0571	0.17	CbGbCtD
Naltrexone—UGT1A1—Etoposide—lung cancer	0.0458	0.136	CbGbCtD
Naltrexone—ABCB1—Topotecan—lung cancer	0.0232	0.0689	CbGbCtD
Naltrexone—ABCB1—Gefitinib—lung cancer	0.0212	0.063	CbGbCtD
Naltrexone—ABCB1—Vinorelbine—lung cancer	0.0164	0.0485	CbGbCtD
Naltrexone—ABCB1—Crizotinib—lung cancer	0.013	0.0386	CbGbCtD
Naltrexone—ABCB1—Gemcitabine—lung cancer	0.0127	0.0377	CbGbCtD
Naltrexone—ABCB1—Erlotinib—lung cancer	0.0126	0.0372	CbGbCtD
Naltrexone—ABCB1—Paclitaxel—lung cancer	0.0115	0.0341	CbGbCtD
Naltrexone—ABCB1—Irinotecan—lung cancer	0.0113	0.0336	CbGbCtD
Naltrexone—ABCB1—Vinblastine—lung cancer	0.0101	0.0299	CbGbCtD
Naltrexone—ABCB1—Cisplatin—lung cancer	0.00924	0.0274	CbGbCtD
Naltrexone—ABCB1—Etoposide—lung cancer	0.00908	0.0269	CbGbCtD
Naltrexone—ABCB1—Docetaxel—lung cancer	0.00831	0.0246	CbGbCtD
Naltrexone—ABCB1—Doxorubicin—lung cancer	0.00619	0.0184	CbGbCtD
Naltrexone—ABCB1—Methotrexate—lung cancer	0.006	0.0178	CbGbCtD
Naltrexone—Morphine—UGT1A1—lung cancer	0.000513	0.286	CrCbGaD
Naltrexone—Buprenorphine—CYP2A6—lung cancer	0.000385	0.214	CrCbGaD
Naltrexone—Buprenorphine—ABCG2—lung cancer	0.000344	0.192	CrCbGaD
Naltrexone—Naloxone—ALB—lung cancer	0.000149	0.0829	CrCbGaD
Naltrexone—Buprenorphine—ABCB1—lung cancer	0.000143	0.0797	CrCbGaD
Naltrexone—Naloxone—ABCB1—lung cancer	0.000142	0.0792	CrCbGaD
Naltrexone—Morphine—ABCB1—lung cancer	0.00012	0.0668	CrCbGaD
Naltrexone—Hepatobiliary disease—Methotrexate—lung cancer	5.78e-05	0.000414	CcSEcCtD
Naltrexone—Insomnia—Paclitaxel—lung cancer	5.77e-05	0.000414	CcSEcCtD
Naltrexone—Epistaxis—Methotrexate—lung cancer	5.76e-05	0.000413	CcSEcCtD
Naltrexone—Hypersensitivity—Irinotecan—lung cancer	5.76e-05	0.000413	CcSEcCtD
Naltrexone—Convulsion—Docetaxel—lung cancer	5.74e-05	0.000412	CcSEcCtD
Naltrexone—Paraesthesia—Paclitaxel—lung cancer	5.73e-05	0.000411	CcSEcCtD
Naltrexone—Hypertension—Docetaxel—lung cancer	5.72e-05	0.00041	CcSEcCtD
Naltrexone—Bronchitis—Doxorubicin—lung cancer	5.71e-05	0.000409	CcSEcCtD
Naltrexone—Dyspnoea—Paclitaxel—lung cancer	5.69e-05	0.000408	CcSEcCtD
Naltrexone—Somnolence—Paclitaxel—lung cancer	5.67e-05	0.000407	CcSEcCtD
Naltrexone—Decreased appetite—Etoposide—lung cancer	5.66e-05	0.000405	CcSEcCtD
Naltrexone—Myalgia—Docetaxel—lung cancer	5.64e-05	0.000404	CcSEcCtD
Naltrexone—Chest pain—Docetaxel—lung cancer	5.64e-05	0.000404	CcSEcCtD
Naltrexone—Arthralgia—Docetaxel—lung cancer	5.64e-05	0.000404	CcSEcCtD
Naltrexone—Nausea—Vinorelbine—lung cancer	5.63e-05	0.000404	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Etoposide—lung cancer	5.62e-05	0.000403	CcSEcCtD
Naltrexone—Body temperature increased—Cisplatin—lung cancer	5.62e-05	0.000402	CcSEcCtD
Naltrexone—Asthenia—Irinotecan—lung cancer	5.61e-05	0.000402	CcSEcCtD
Naltrexone—Fatigue—Etoposide—lung cancer	5.61e-05	0.000402	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	5.6e-05	0.000402	CcSEcCtD
Naltrexone—Constipation—Etoposide—lung cancer	5.57e-05	0.000399	CcSEcCtD
Naltrexone—Pain—Etoposide—lung cancer	5.57e-05	0.000399	CcSEcCtD
Naltrexone—Decreased appetite—Paclitaxel—lung cancer	5.55e-05	0.000398	CcSEcCtD
Naltrexone—Dry mouth—Docetaxel—lung cancer	5.52e-05	0.000395	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Doxorubicin—lung cancer	5.52e-05	0.000395	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Paclitaxel—lung cancer	5.51e-05	0.000395	CcSEcCtD
Naltrexone—Fatigue—Paclitaxel—lung cancer	5.5e-05	0.000394	CcSEcCtD
Naltrexone—Hepatitis—Methotrexate—lung cancer	5.49e-05	0.000393	CcSEcCtD
Naltrexone—Asthenia—Gemcitabine—lung cancer	5.47e-05	0.000392	CcSEcCtD
Naltrexone—Pain—Paclitaxel—lung cancer	5.46e-05	0.000391	CcSEcCtD
Naltrexone—Constipation—Paclitaxel—lung cancer	5.46e-05	0.000391	CcSEcCtD
Naltrexone—Confusional state—Docetaxel—lung cancer	5.45e-05	0.000391	CcSEcCtD
Naltrexone—Pharyngitis—Methotrexate—lung cancer	5.45e-05	0.00039	CcSEcCtD
Naltrexone—Anaphylactic shock—Docetaxel—lung cancer	5.41e-05	0.000388	CcSEcCtD
Naltrexone—Oedema—Docetaxel—lung cancer	5.41e-05	0.000388	CcSEcCtD
Naltrexone—Weight increased—Doxorubicin—lung cancer	5.4e-05	0.000387	CcSEcCtD
Naltrexone—Pruritus—Gemcitabine—lung cancer	5.39e-05	0.000386	CcSEcCtD
Naltrexone—Infection—Docetaxel—lung cancer	5.37e-05	0.000385	CcSEcCtD
Naltrexone—Weight decreased—Doxorubicin—lung cancer	5.37e-05	0.000385	CcSEcCtD
Naltrexone—Feeling abnormal—Etoposide—lung cancer	5.36e-05	0.000384	CcSEcCtD
Naltrexone—Diarrhoea—Irinotecan—lung cancer	5.35e-05	0.000384	CcSEcCtD
Naltrexone—Pneumonia—Doxorubicin—lung cancer	5.32e-05	0.000382	CcSEcCtD
Naltrexone—Gastrointestinal pain—Etoposide—lung cancer	5.32e-05	0.000381	CcSEcCtD
Naltrexone—Shock—Docetaxel—lung cancer	5.32e-05	0.000381	CcSEcCtD
Naltrexone—Nervous system disorder—Docetaxel—lung cancer	5.3e-05	0.00038	CcSEcCtD
Naltrexone—Infestation NOS—Doxorubicin—lung cancer	5.29e-05	0.000379	CcSEcCtD
Naltrexone—Infestation—Doxorubicin—lung cancer	5.29e-05	0.000379	CcSEcCtD
Naltrexone—Tachycardia—Docetaxel—lung cancer	5.28e-05	0.000378	CcSEcCtD
Naltrexone—Feeling abnormal—Paclitaxel—lung cancer	5.26e-05	0.000377	CcSEcCtD
Naltrexone—Skin disorder—Docetaxel—lung cancer	5.25e-05	0.000377	CcSEcCtD
Naltrexone—Hypersensitivity—Cisplatin—lung cancer	5.23e-05	0.000375	CcSEcCtD
Naltrexone—Gastrointestinal pain—Paclitaxel—lung cancer	5.22e-05	0.000374	CcSEcCtD
Naltrexone—Diarrhoea—Gemcitabine—lung cancer	5.21e-05	0.000374	CcSEcCtD
Naltrexone—Dizziness—Irinotecan—lung cancer	5.17e-05	0.000371	CcSEcCtD
Naltrexone—Urticaria—Etoposide—lung cancer	5.17e-05	0.000371	CcSEcCtD
Naltrexone—Anorexia—Docetaxel—lung cancer	5.16e-05	0.000369	CcSEcCtD
Naltrexone—Body temperature increased—Etoposide—lung cancer	5.14e-05	0.000369	CcSEcCtD
Naltrexone—Abdominal pain—Etoposide—lung cancer	5.14e-05	0.000369	CcSEcCtD
Naltrexone—Conjunctivitis—Doxorubicin—lung cancer	5.14e-05	0.000369	CcSEcCtD
Naltrexone—Urinary tract infection—Doxorubicin—lung cancer	5.14e-05	0.000369	CcSEcCtD
Naltrexone—Eye disorder—Methotrexate—lung cancer	5.13e-05	0.000367	CcSEcCtD
Naltrexone—Tinnitus—Methotrexate—lung cancer	5.12e-05	0.000367	CcSEcCtD
Naltrexone—Asthenia—Cisplatin—lung cancer	5.1e-05	0.000365	CcSEcCtD
Naltrexone—Cardiac disorder—Methotrexate—lung cancer	5.09e-05	0.000365	CcSEcCtD
Naltrexone—Urticaria—Paclitaxel—lung cancer	5.07e-05	0.000363	CcSEcCtD
Naltrexone—Body temperature increased—Paclitaxel—lung cancer	5.04e-05	0.000362	CcSEcCtD
Naltrexone—Abdominal pain—Paclitaxel—lung cancer	5.04e-05	0.000362	CcSEcCtD
Naltrexone—Hepatobiliary disease—Doxorubicin—lung cancer	5.01e-05	0.000359	CcSEcCtD
Naltrexone—Epistaxis—Doxorubicin—lung cancer	4.99e-05	0.000358	CcSEcCtD
Naltrexone—Angiopathy—Methotrexate—lung cancer	4.98e-05	0.000357	CcSEcCtD
Naltrexone—Vomiting—Irinotecan—lung cancer	4.97e-05	0.000357	CcSEcCtD
Naltrexone—Sinusitis—Doxorubicin—lung cancer	4.97e-05	0.000356	CcSEcCtD
Naltrexone—Immune system disorder—Methotrexate—lung cancer	4.96e-05	0.000355	CcSEcCtD
Naltrexone—Mediastinal disorder—Methotrexate—lung cancer	4.94e-05	0.000354	CcSEcCtD
Naltrexone—Rash—Irinotecan—lung cancer	4.93e-05	0.000354	CcSEcCtD
Naltrexone—Dermatitis—Irinotecan—lung cancer	4.93e-05	0.000353	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Docetaxel—lung cancer	4.93e-05	0.000353	CcSEcCtD
Naltrexone—Chills—Methotrexate—lung cancer	4.92e-05	0.000353	CcSEcCtD
Naltrexone—Headache—Irinotecan—lung cancer	4.9e-05	0.000351	CcSEcCtD
Naltrexone—Insomnia—Docetaxel—lung cancer	4.89e-05	0.000351	CcSEcCtD
Naltrexone—Diarrhoea—Cisplatin—lung cancer	4.86e-05	0.000348	CcSEcCtD
Naltrexone—Paraesthesia—Docetaxel—lung cancer	4.86e-05	0.000348	CcSEcCtD
Naltrexone—Alopecia—Methotrexate—lung cancer	4.85e-05	0.000347	CcSEcCtD
Naltrexone—Vomiting—Gemcitabine—lung cancer	4.85e-05	0.000347	CcSEcCtD
Naltrexone—Dyspnoea—Docetaxel—lung cancer	4.82e-05	0.000346	CcSEcCtD
Naltrexone—Somnolence—Docetaxel—lung cancer	4.81e-05	0.000345	CcSEcCtD
Naltrexone—Mental disorder—Methotrexate—lung cancer	4.81e-05	0.000345	CcSEcCtD
Naltrexone—Rash—Gemcitabine—lung cancer	4.81e-05	0.000344	CcSEcCtD
Naltrexone—Dermatitis—Gemcitabine—lung cancer	4.8e-05	0.000344	CcSEcCtD
Naltrexone—Hypersensitivity—Etoposide—lung cancer	4.79e-05	0.000344	CcSEcCtD
Naltrexone—Malnutrition—Methotrexate—lung cancer	4.78e-05	0.000342	CcSEcCtD
Naltrexone—Headache—Gemcitabine—lung cancer	4.77e-05	0.000342	CcSEcCtD
Naltrexone—Hepatitis—Doxorubicin—lung cancer	4.75e-05	0.000341	CcSEcCtD
Naltrexone—Pharyngitis—Doxorubicin—lung cancer	4.72e-05	0.000338	CcSEcCtD
Naltrexone—Decreased appetite—Docetaxel—lung cancer	4.7e-05	0.000337	CcSEcCtD
Naltrexone—Hypersensitivity—Paclitaxel—lung cancer	4.7e-05	0.000337	CcSEcCtD
Naltrexone—Dysgeusia—Methotrexate—lung cancer	4.68e-05	0.000335	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Docetaxel—lung cancer	4.67e-05	0.000335	CcSEcCtD
Naltrexone—Asthenia—Etoposide—lung cancer	4.67e-05	0.000335	CcSEcCtD
Naltrexone—Connective tissue disorder—Doxorubicin—lung cancer	4.67e-05	0.000335	CcSEcCtD
Naltrexone—Fatigue—Docetaxel—lung cancer	4.66e-05	0.000334	CcSEcCtD
Naltrexone—Nausea—Irinotecan—lung cancer	4.65e-05	0.000333	CcSEcCtD
Naltrexone—Pain—Docetaxel—lung cancer	4.62e-05	0.000331	CcSEcCtD
Naltrexone—Constipation—Docetaxel—lung cancer	4.62e-05	0.000331	CcSEcCtD
Naltrexone—Back pain—Methotrexate—lung cancer	4.62e-05	0.000331	CcSEcCtD
Naltrexone—Pruritus—Etoposide—lung cancer	4.6e-05	0.00033	CcSEcCtD
Naltrexone—Asthenia—Paclitaxel—lung cancer	4.58e-05	0.000328	CcSEcCtD
Naltrexone—Nausea—Gemcitabine—lung cancer	4.53e-05	0.000324	CcSEcCtD
Naltrexone—Vomiting—Cisplatin—lung cancer	4.52e-05	0.000324	CcSEcCtD
Naltrexone—Pruritus—Paclitaxel—lung cancer	4.51e-05	0.000324	CcSEcCtD
Naltrexone—Vision blurred—Methotrexate—lung cancer	4.5e-05	0.000323	CcSEcCtD
Naltrexone—Rash—Cisplatin—lung cancer	4.48e-05	0.000321	CcSEcCtD
Naltrexone—Dermatitis—Cisplatin—lung cancer	4.47e-05	0.000321	CcSEcCtD
Naltrexone—Feeling abnormal—Docetaxel—lung cancer	4.46e-05	0.000319	CcSEcCtD
Naltrexone—Diarrhoea—Etoposide—lung cancer	4.45e-05	0.000319	CcSEcCtD
Naltrexone—Eye disorder—Doxorubicin—lung cancer	4.44e-05	0.000318	CcSEcCtD
Naltrexone—Ill-defined disorder—Methotrexate—lung cancer	4.43e-05	0.000318	CcSEcCtD
Naltrexone—Tinnitus—Doxorubicin—lung cancer	4.43e-05	0.000317	CcSEcCtD
Naltrexone—Gastrointestinal pain—Docetaxel—lung cancer	4.42e-05	0.000317	CcSEcCtD
Naltrexone—Cardiac disorder—Doxorubicin—lung cancer	4.41e-05	0.000316	CcSEcCtD
Naltrexone—Diarrhoea—Paclitaxel—lung cancer	4.37e-05	0.000313	CcSEcCtD
Naltrexone—Angiopathy—Doxorubicin—lung cancer	4.31e-05	0.000309	CcSEcCtD
Naltrexone—Malaise—Methotrexate—lung cancer	4.31e-05	0.000309	CcSEcCtD
Naltrexone—Dizziness—Etoposide—lung cancer	4.3e-05	0.000308	CcSEcCtD
Naltrexone—Immune system disorder—Doxorubicin—lung cancer	4.29e-05	0.000308	CcSEcCtD
Naltrexone—Mediastinal disorder—Doxorubicin—lung cancer	4.28e-05	0.000307	CcSEcCtD
Naltrexone—Abdominal pain—Docetaxel—lung cancer	4.28e-05	0.000306	CcSEcCtD
Naltrexone—Body temperature increased—Docetaxel—lung cancer	4.28e-05	0.000306	CcSEcCtD
Naltrexone—Chills—Doxorubicin—lung cancer	4.26e-05	0.000306	CcSEcCtD
Naltrexone—Dizziness—Paclitaxel—lung cancer	4.22e-05	0.000302	CcSEcCtD
Naltrexone—Nausea—Cisplatin—lung cancer	4.22e-05	0.000302	CcSEcCtD
Naltrexone—Alopecia—Doxorubicin—lung cancer	4.2e-05	0.000301	CcSEcCtD
Naltrexone—Cough—Methotrexate—lung cancer	4.17e-05	0.000299	CcSEcCtD
Naltrexone—Mental disorder—Doxorubicin—lung cancer	4.16e-05	0.000298	CcSEcCtD
Naltrexone—Convulsion—Methotrexate—lung cancer	4.14e-05	0.000297	CcSEcCtD
Naltrexone—Vomiting—Etoposide—lung cancer	4.14e-05	0.000297	CcSEcCtD
Naltrexone—Malnutrition—Doxorubicin—lung cancer	4.14e-05	0.000296	CcSEcCtD
Naltrexone—Rash—Etoposide—lung cancer	4.1e-05	0.000294	CcSEcCtD
Naltrexone—Dermatitis—Etoposide—lung cancer	4.1e-05	0.000294	CcSEcCtD
Naltrexone—Headache—Etoposide—lung cancer	4.08e-05	0.000292	CcSEcCtD
Naltrexone—Flatulence—Doxorubicin—lung cancer	4.08e-05	0.000292	CcSEcCtD
Naltrexone—Myalgia—Methotrexate—lung cancer	4.07e-05	0.000291	CcSEcCtD
Naltrexone—Chest pain—Methotrexate—lung cancer	4.07e-05	0.000291	CcSEcCtD
Naltrexone—Arthralgia—Methotrexate—lung cancer	4.07e-05	0.000291	CcSEcCtD
Naltrexone—Tension—Doxorubicin—lung cancer	4.06e-05	0.000291	CcSEcCtD
Naltrexone—Vomiting—Paclitaxel—lung cancer	4.06e-05	0.000291	CcSEcCtD
Naltrexone—Dysgeusia—Doxorubicin—lung cancer	4.05e-05	0.00029	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	4.04e-05	0.000289	CcSEcCtD
Naltrexone—Rash—Paclitaxel—lung cancer	4.02e-05	0.000288	CcSEcCtD
Naltrexone—Dermatitis—Paclitaxel—lung cancer	4.02e-05	0.000288	CcSEcCtD
Naltrexone—Discomfort—Methotrexate—lung cancer	4.02e-05	0.000288	CcSEcCtD
Naltrexone—Nervousness—Doxorubicin—lung cancer	4.02e-05	0.000288	CcSEcCtD
Naltrexone—Back pain—Doxorubicin—lung cancer	4e-05	0.000287	CcSEcCtD
Naltrexone—Headache—Paclitaxel—lung cancer	4e-05	0.000286	CcSEcCtD
Naltrexone—Hypersensitivity—Docetaxel—lung cancer	3.98e-05	0.000286	CcSEcCtD
Naltrexone—Muscle spasms—Doxorubicin—lung cancer	3.98e-05	0.000285	CcSEcCtD
Naltrexone—Confusional state—Methotrexate—lung cancer	3.93e-05	0.000282	CcSEcCtD
Naltrexone—Anaphylactic shock—Methotrexate—lung cancer	3.9e-05	0.000279	CcSEcCtD
Naltrexone—Vision blurred—Doxorubicin—lung cancer	3.9e-05	0.000279	CcSEcCtD
Naltrexone—Asthenia—Docetaxel—lung cancer	3.88e-05	0.000278	CcSEcCtD
Naltrexone—Infection—Methotrexate—lung cancer	3.87e-05	0.000278	CcSEcCtD
Naltrexone—Nausea—Etoposide—lung cancer	3.87e-05	0.000277	CcSEcCtD
Naltrexone—Ill-defined disorder—Doxorubicin—lung cancer	3.84e-05	0.000275	CcSEcCtD
Naltrexone—Pruritus—Docetaxel—lung cancer	3.83e-05	0.000274	CcSEcCtD
Naltrexone—Nervous system disorder—Methotrexate—lung cancer	3.82e-05	0.000274	CcSEcCtD
Naltrexone—Agitation—Doxorubicin—lung cancer	3.8e-05	0.000272	CcSEcCtD
Naltrexone—Nausea—Paclitaxel—lung cancer	3.79e-05	0.000272	CcSEcCtD
Naltrexone—Skin disorder—Methotrexate—lung cancer	3.79e-05	0.000271	CcSEcCtD
Naltrexone—Hyperhidrosis—Methotrexate—lung cancer	3.77e-05	0.00027	CcSEcCtD
Naltrexone—Malaise—Doxorubicin—lung cancer	3.73e-05	0.000267	CcSEcCtD
Naltrexone—Anorexia—Methotrexate—lung cancer	3.72e-05	0.000266	CcSEcCtD
Naltrexone—Syncope—Doxorubicin—lung cancer	3.71e-05	0.000266	CcSEcCtD
Naltrexone—Diarrhoea—Docetaxel—lung cancer	3.7e-05	0.000265	CcSEcCtD
Naltrexone—Palpitations—Doxorubicin—lung cancer	3.65e-05	0.000262	CcSEcCtD
Naltrexone—Loss of consciousness—Doxorubicin—lung cancer	3.64e-05	0.000261	CcSEcCtD
Naltrexone—Cough—Doxorubicin—lung cancer	3.61e-05	0.000259	CcSEcCtD
Naltrexone—Convulsion—Doxorubicin—lung cancer	3.58e-05	0.000257	CcSEcCtD
Naltrexone—Dizziness—Docetaxel—lung cancer	3.58e-05	0.000256	CcSEcCtD
Naltrexone—Hypertension—Doxorubicin—lung cancer	3.57e-05	0.000256	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Methotrexate—lung cancer	3.55e-05	0.000255	CcSEcCtD
Naltrexone—Insomnia—Methotrexate—lung cancer	3.53e-05	0.000253	CcSEcCtD
Naltrexone—Chest pain—Doxorubicin—lung cancer	3.52e-05	0.000252	CcSEcCtD
Naltrexone—Myalgia—Doxorubicin—lung cancer	3.52e-05	0.000252	CcSEcCtD
Naltrexone—Arthralgia—Doxorubicin—lung cancer	3.52e-05	0.000252	CcSEcCtD
Naltrexone—Anxiety—Doxorubicin—lung cancer	3.51e-05	0.000251	CcSEcCtD
Naltrexone—Paraesthesia—Methotrexate—lung cancer	3.5e-05	0.000251	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	3.5e-05	0.000251	CcSEcCtD
Naltrexone—Discomfort—Doxorubicin—lung cancer	3.48e-05	0.000249	CcSEcCtD
Naltrexone—Dyspnoea—Methotrexate—lung cancer	3.48e-05	0.000249	CcSEcCtD
Naltrexone—Somnolence—Methotrexate—lung cancer	3.47e-05	0.000248	CcSEcCtD
Naltrexone—Dry mouth—Doxorubicin—lung cancer	3.44e-05	0.000247	CcSEcCtD
Naltrexone—Vomiting—Docetaxel—lung cancer	3.44e-05	0.000246	CcSEcCtD
Naltrexone—Rash—Docetaxel—lung cancer	3.41e-05	0.000244	CcSEcCtD
Naltrexone—Dermatitis—Docetaxel—lung cancer	3.41e-05	0.000244	CcSEcCtD
Naltrexone—Confusional state—Doxorubicin—lung cancer	3.4e-05	0.000244	CcSEcCtD
Naltrexone—Decreased appetite—Methotrexate—lung cancer	3.39e-05	0.000243	CcSEcCtD
Naltrexone—Headache—Docetaxel—lung cancer	3.39e-05	0.000243	CcSEcCtD
Naltrexone—Oedema—Doxorubicin—lung cancer	3.38e-05	0.000242	CcSEcCtD
Naltrexone—Anaphylactic shock—Doxorubicin—lung cancer	3.38e-05	0.000242	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Methotrexate—lung cancer	3.37e-05	0.000241	CcSEcCtD
Naltrexone—Fatigue—Methotrexate—lung cancer	3.36e-05	0.000241	CcSEcCtD
Naltrexone—Infection—Doxorubicin—lung cancer	3.35e-05	0.00024	CcSEcCtD
Naltrexone—Pain—Methotrexate—lung cancer	3.33e-05	0.000239	CcSEcCtD
Naltrexone—Shock—Doxorubicin—lung cancer	3.32e-05	0.000238	CcSEcCtD
Naltrexone—Nervous system disorder—Doxorubicin—lung cancer	3.31e-05	0.000237	CcSEcCtD
Naltrexone—Tachycardia—Doxorubicin—lung cancer	3.29e-05	0.000236	CcSEcCtD
Naltrexone—Skin disorder—Doxorubicin—lung cancer	3.28e-05	0.000235	CcSEcCtD
Naltrexone—Hyperhidrosis—Doxorubicin—lung cancer	3.26e-05	0.000234	CcSEcCtD
Naltrexone—Anorexia—Doxorubicin—lung cancer	3.22e-05	0.000231	CcSEcCtD
Naltrexone—Nausea—Docetaxel—lung cancer	3.21e-05	0.00023	CcSEcCtD
Naltrexone—Feeling abnormal—Methotrexate—lung cancer	3.21e-05	0.00023	CcSEcCtD
Naltrexone—Gastrointestinal pain—Methotrexate—lung cancer	3.19e-05	0.000228	CcSEcCtD
Naltrexone—Urticaria—Methotrexate—lung cancer	3.1e-05	0.000222	CcSEcCtD
Naltrexone—Body temperature increased—Methotrexate—lung cancer	3.08e-05	0.000221	CcSEcCtD
Naltrexone—Abdominal pain—Methotrexate—lung cancer	3.08e-05	0.000221	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Doxorubicin—lung cancer	3.08e-05	0.00022	CcSEcCtD
Naltrexone—Insomnia—Doxorubicin—lung cancer	3.05e-05	0.000219	CcSEcCtD
Naltrexone—Paraesthesia—Doxorubicin—lung cancer	3.03e-05	0.000217	CcSEcCtD
Naltrexone—Dyspnoea—Doxorubicin—lung cancer	3.01e-05	0.000216	CcSEcCtD
Naltrexone—Somnolence—Doxorubicin—lung cancer	3e-05	0.000215	CcSEcCtD
Naltrexone—Decreased appetite—Doxorubicin—lung cancer	2.93e-05	0.00021	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Doxorubicin—lung cancer	2.91e-05	0.000209	CcSEcCtD
Naltrexone—Fatigue—Doxorubicin—lung cancer	2.91e-05	0.000209	CcSEcCtD
Naltrexone—Pain—Doxorubicin—lung cancer	2.89e-05	0.000207	CcSEcCtD
Naltrexone—Constipation—Doxorubicin—lung cancer	2.89e-05	0.000207	CcSEcCtD
Naltrexone—Hypersensitivity—Methotrexate—lung cancer	2.87e-05	0.000206	CcSEcCtD
Naltrexone—Asthenia—Methotrexate—lung cancer	2.8e-05	0.0002	CcSEcCtD
Naltrexone—Feeling abnormal—Doxorubicin—lung cancer	2.78e-05	0.000199	CcSEcCtD
Naltrexone—Gastrointestinal pain—Doxorubicin—lung cancer	2.76e-05	0.000198	CcSEcCtD
Naltrexone—Pruritus—Methotrexate—lung cancer	2.76e-05	0.000198	CcSEcCtD
Naltrexone—Urticaria—Doxorubicin—lung cancer	2.68e-05	0.000192	CcSEcCtD
Naltrexone—Abdominal pain—Doxorubicin—lung cancer	2.67e-05	0.000191	CcSEcCtD
Naltrexone—Body temperature increased—Doxorubicin—lung cancer	2.67e-05	0.000191	CcSEcCtD
Naltrexone—Diarrhoea—Methotrexate—lung cancer	2.67e-05	0.000191	CcSEcCtD
Naltrexone—Dizziness—Methotrexate—lung cancer	2.58e-05	0.000185	CcSEcCtD
Naltrexone—Hypersensitivity—Doxorubicin—lung cancer	2.49e-05	0.000178	CcSEcCtD
Naltrexone—Vomiting—Methotrexate—lung cancer	2.48e-05	0.000178	CcSEcCtD
Naltrexone—Rash—Methotrexate—lung cancer	2.46e-05	0.000176	CcSEcCtD
Naltrexone—Dermatitis—Methotrexate—lung cancer	2.46e-05	0.000176	CcSEcCtD
Naltrexone—Headache—Methotrexate—lung cancer	2.44e-05	0.000175	CcSEcCtD
Naltrexone—Asthenia—Doxorubicin—lung cancer	2.42e-05	0.000174	CcSEcCtD
Naltrexone—Pruritus—Doxorubicin—lung cancer	2.39e-05	0.000171	CcSEcCtD
Naltrexone—Nausea—Methotrexate—lung cancer	2.32e-05	0.000166	CcSEcCtD
Naltrexone—Diarrhoea—Doxorubicin—lung cancer	2.31e-05	0.000166	CcSEcCtD
Naltrexone—Dizziness—Doxorubicin—lung cancer	2.23e-05	0.00016	CcSEcCtD
Naltrexone—Vomiting—Doxorubicin—lung cancer	2.15e-05	0.000154	CcSEcCtD
Naltrexone—Rash—Doxorubicin—lung cancer	2.13e-05	0.000153	CcSEcCtD
Naltrexone—Dermatitis—Doxorubicin—lung cancer	2.13e-05	0.000152	CcSEcCtD
Naltrexone—Headache—Doxorubicin—lung cancer	2.11e-05	0.000152	CcSEcCtD
Naltrexone—Nausea—Doxorubicin—lung cancer	2e-05	0.000144	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—ERBB3—lung cancer	1.17e-05	0.000267	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—TYMS—lung cancer	1.17e-05	0.000267	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—lung cancer	1.17e-05	0.000266	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTM1—lung cancer	1.16e-05	0.000264	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTA4—lung cancer	1.16e-05	0.000263	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CD—lung cancer	1.15e-05	0.000262	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF1R—lung cancer	1.15e-05	0.000261	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL8—lung cancer	1.14e-05	0.00026	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—lung cancer	1.14e-05	0.00026	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—POMC—lung cancer	1.13e-05	0.000258	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL2—lung cancer	1.13e-05	0.000257	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTA2—lung cancer	1.13e-05	0.000257	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HES1—lung cancer	1.13e-05	0.000257	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TERT—lung cancer	1.12e-05	0.000256	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STK11—lung cancer	1.11e-05	0.000253	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—RAF1—lung cancer	1.1e-05	0.000252	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6R—lung cancer	1.1e-05	0.000252	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP1A1—lung cancer	1.1e-05	0.00025	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FGFR1—lung cancer	1.09e-05	0.000249	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—IL2—lung cancer	1.09e-05	0.000248	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ERCC2—lung cancer	1.09e-05	0.000248	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTA1—lung cancer	1.09e-05	0.000248	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CB—lung cancer	1.08e-05	0.000246	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—lung cancer	1.08e-05	0.000245	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HIF1A—lung cancer	1.08e-05	0.000245	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ABCC3—lung cancer	1.07e-05	0.000245	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FOXO3—lung cancer	1.07e-05	0.000245	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAP2K1—lung cancer	1.05e-05	0.00024	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CD—lung cancer	1.04e-05	0.000238	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKR1C1—lung cancer	1.04e-05	0.000237	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APOA1—lung cancer	1.04e-05	0.000237	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL8—lung cancer	1.04e-05	0.000236	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ERBB3—lung cancer	1.03e-05	0.000235	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KDR—lung cancer	1.03e-05	0.000234	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—UGT1A1—lung cancer	1.01e-05	0.00023	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AVP—lung cancer	1.01e-05	0.000229	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CB—lung cancer	1e-05	0.000229	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL2—lung cancer	9.9e-06	0.000226	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—lung cancer	9.9e-06	0.000226	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TERT—lung cancer	9.86e-06	0.000225	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GNG11—lung cancer	9.74e-06	0.000222	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1R—lung cancer	9.68e-06	0.000221	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL8—lung cancer	9.64e-06	0.00022	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGFR1—lung cancer	9.58e-06	0.000218	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—lung cancer	9.57e-06	0.000218	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HES1—lung cancer	9.51e-06	0.000217	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CG—lung cancer	9.48e-06	0.000216	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APC—lung cancer	9.48e-06	0.000216	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KIT—lung cancer	9.48e-06	0.000216	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—NRAS—lung cancer	9.47e-06	0.000216	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HIF1A—lung cancer	9.43e-06	0.000215	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—APOA1—lung cancer	9.41e-06	0.000214	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGF—lung cancer	9.37e-06	0.000213	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—RAF1—lung cancer	9.33e-06	0.000213	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALDOA—lung cancer	9.27e-06	0.000211	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—APOA1—lung cancer	9.21e-06	0.00021	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—IL2—lung cancer	9.21e-06	0.00021	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CB—lung cancer	9.11e-06	0.000208	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APOA1—lung cancer	9.1e-06	0.000207	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MAPK3—lung cancer	9.07e-06	0.000207	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—POMC—lung cancer	9.02e-06	0.000206	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KDR—lung cancer	9.02e-06	0.000206	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NCOA3—lung cancer	9e-06	0.000205	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—BRAF—lung cancer	8.91e-06	0.000203	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6R—lung cancer	8.8e-06	0.000201	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CREBBP—lung cancer	8.78e-06	0.0002	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ABCG2—lung cancer	8.76e-06	0.0002	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ADCY1—lung cancer	8.76e-06	0.0002	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL8—lung cancer	8.75e-06	0.0002	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ERBB3—lung cancer	8.7e-06	0.000198	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EGFR—lung cancer	8.63e-06	0.000197	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HPGDS—lung cancer	8.59e-06	0.000196	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ENO2—lung cancer	8.59e-06	0.000196	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CG—lung cancer	8.59e-06	0.000196	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPP2R1B—lung cancer	8.53e-06	0.000195	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAP2K1—lung cancer	8.38e-06	0.000191	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL2—lung cancer	8.36e-06	0.000191	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TERT—lung cancer	8.33e-06	0.00019	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CD—lung cancer	8.33e-06	0.00019	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTT1—lung cancer	8.33e-06	0.00019	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APC—lung cancer	8.31e-06	0.000189	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KIT—lung cancer	8.31e-06	0.000189	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CG—lung cancer	8.31e-06	0.000189	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—NRAS—lung cancer	8.31e-06	0.000189	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CA—lung cancer	8.25e-06	0.000188	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GCLC—lung cancer	8.23e-06	0.000188	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2A6—lung cancer	8.23e-06	0.000188	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGF—lung cancer	8.21e-06	0.000187	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—POMC—lung cancer	8.17e-06	0.000186	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—KRAS—lung cancer	8.15e-06	0.000186	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGFR1—lung cancer	8.09e-06	0.000184	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	8.08e-06	0.000184	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HIF1A—lung cancer	7.97e-06	0.000182	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CREBBP—lung cancer	7.96e-06	0.000181	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MAPK3—lung cancer	7.96e-06	0.000181	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—POMC—lung cancer	7.91e-06	0.00018	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—BRAF—lung cancer	7.81e-06	0.000178	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ENO1—lung cancer	7.81e-06	0.000178	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—CREBBP—lung cancer	7.8e-06	0.000178	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6R—lung cancer	7.71e-06	0.000176	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CREBBP—lung cancer	7.7e-06	0.000176	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOA1—lung cancer	7.69e-06	0.000175	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KDR—lung cancer	7.62e-06	0.000174	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EGFR—lung cancer	7.57e-06	0.000173	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CD—lung cancer	7.55e-06	0.000172	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CA—lung cancer	7.49e-06	0.000171	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MDM2—lung cancer	7.46e-06	0.00017	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALB—lung cancer	7.45e-06	0.00017	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RAF1—lung cancer	7.44e-06	0.000169	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ERBB2—lung cancer	7.36e-06	0.000168	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAP2K1—lung cancer	7.35e-06	0.000168	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CD—lung cancer	7.3e-06	0.000166	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ALB—lung cancer	7.3e-06	0.000166	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CB—lung cancer	7.26e-06	0.000165	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MTOR—lung cancer	7.26e-06	0.000165	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CA—lung cancer	7.23e-06	0.000165	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—KRAS—lung cancer	7.15e-06	0.000163	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KIT—lung cancer	7.02e-06	0.00016	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APC—lung cancer	7.02e-06	0.00016	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CG—lung cancer	7.02e-06	0.00016	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—NRAS—lung cancer	7.02e-06	0.00016	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2E1—lung cancer	7e-06	0.00016	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL8—lung cancer	6.98e-06	0.000159	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGF—lung cancer	6.94e-06	0.000158	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HRAS—lung cancer	6.93e-06	0.000158	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NQO1—lung cancer	6.92e-06	0.000158	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AKT1—lung cancer	6.74e-06	0.000154	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAPK3—lung cancer	6.72e-06	0.000153	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—POMC—lung cancer	6.68e-06	0.000152	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CASP3—lung cancer	6.68e-06	0.000152	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL2—lung cancer	6.67e-06	0.000152	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—lung cancer	6.63e-06	0.000151	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—RAF1—lung cancer	6.6e-06	0.00015	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—BRAF—lung cancer	6.6e-06	0.00015	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CB—lung cancer	6.58e-06	0.00015	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CA—lung cancer	6.57e-06	0.00015	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MDM2—lung cancer	6.54e-06	0.000149	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RAF1—lung cancer	6.52e-06	0.000149	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6R—lung cancer	6.52e-06	0.000149	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—lung cancer	6.52e-06	0.000149	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CREBBP—lung cancer	6.51e-06	0.000148	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCND1—lung cancer	6.5e-06	0.000148	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—JUN—lung cancer	6.49e-06	0.000148	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ERBB2—lung cancer	6.45e-06	0.000147	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EGFR—lung cancer	6.4e-06	0.000146	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CB—lung cancer	6.37e-06	0.000145	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MTOR—lung cancer	6.37e-06	0.000145	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—lung cancer	6.31e-06	0.000144	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1A—lung cancer	6.29e-06	0.000143	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTEN—lung cancer	6.27e-06	0.000143	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—STK11—lung cancer	6.24e-06	0.000142	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAP2K1—lung cancer	6.21e-06	0.000142	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CD—lung cancer	6.17e-06	0.000141	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AKT1—lung cancer	6.12e-06	0.00014	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL8—lung cancer	6.12e-06	0.000139	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CA—lung cancer	6.11e-06	0.000139	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HRAS—lung cancer	6.08e-06	0.000139	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—KRAS—lung cancer	6.04e-06	0.000138	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EP300—lung cancer	5.98e-06	0.000136	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AKT1—lung cancer	5.91e-06	0.000135	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CASP3—lung cancer	5.86e-06	0.000133	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL2—lung cancer	5.85e-06	0.000133	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SRC—lung cancer	5.82e-06	0.000133	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—lung cancer	5.82e-06	0.000133	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTP1—lung cancer	5.77e-06	0.000132	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCND1—lung cancer	5.7e-06	0.00013	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JUN—lung cancer	5.69e-06	0.00013	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTEN—lung cancer	5.69e-06	0.00013	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—lung cancer	5.67e-06	0.000129	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CAT—lung cancer	5.62e-06	0.000128	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STAT3—lung cancer	5.61e-06	0.000128	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NRAS—lung cancer	5.6e-06	0.000128	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CA—lung cancer	5.55e-06	0.000127	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—lung cancer	5.53e-06	0.000126	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MDM2—lung cancer	5.53e-06	0.000126	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1A—lung cancer	5.51e-06	0.000126	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RAF1—lung cancer	5.51e-06	0.000126	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTEN—lung cancer	5.5e-06	0.000125	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ERBB2—lung cancer	5.45e-06	0.000124	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—EP300—lung cancer	5.42e-06	0.000124	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CB—lung cancer	5.38e-06	0.000123	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MTOR—lung cancer	5.38e-06	0.000123	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TYMS—lung cancer	5.37e-06	0.000122	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT1—lung cancer	5.37e-06	0.000122	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK3—lung cancer	5.36e-06	0.000122	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTM1—lung cancer	5.31e-06	0.000121	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EP300—lung cancer	5.25e-06	0.00012	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MYC—lung cancer	5.21e-06	0.000119	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL8—lung cancer	5.17e-06	0.000118	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HRAS—lung cancer	5.14e-06	0.000117	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SRC—lung cancer	5.1e-06	0.000116	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGFR—lung cancer	5.1e-06	0.000116	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP1A1—lung cancer	5.03e-06	0.000115	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT1—lung cancer	4.99e-06	0.000114	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ERCC2—lung cancer	4.99e-06	0.000114	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—lung cancer	4.97e-06	0.000113	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CASP3—lung cancer	4.95e-06	0.000113	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL2—lung cancer	4.94e-06	0.000113	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STAT3—lung cancer	4.92e-06	0.000112	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—lung cancer	4.92e-06	0.000112	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NRAS—lung cancer	4.91e-06	0.000112	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KRAS—lung cancer	4.82e-06	0.00011	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCND1—lung cancer	4.82e-06	0.00011	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JUN—lung cancer	4.81e-06	0.00011	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK3—lung cancer	4.7e-06	0.000107	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—lung cancer	4.68e-06	0.000107	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1A—lung cancer	4.66e-06	0.000106	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTEN—lung cancer	4.65e-06	0.000106	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MYC—lung cancer	4.57e-06	0.000104	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT1—lung cancer	4.54e-06	0.000103	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGFR—lung cancer	4.47e-06	0.000102	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EP300—lung cancer	4.43e-06	0.000101	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CA—lung cancer	4.43e-06	0.000101	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOA1—lung cancer	4.32e-06	9.84e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SRC—lung cancer	4.31e-06	9.83e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—lung cancer	4.28e-06	9.76e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KRAS—lung cancer	4.22e-06	9.63e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—lung cancer	4.2e-06	9.57e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STAT3—lung cancer	4.16e-06	9.48e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NRAS—lung cancer	4.15e-06	9.45e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HRAS—lung cancer	4.09e-06	9.33e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CA—lung cancer	4.01e-06	9.14e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK3—lung cancer	3.97e-06	9.05e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CG—lung cancer	3.94e-06	8.98e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—lung cancer	3.92e-06	8.93e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CA—lung cancer	3.88e-06	8.85e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MYC—lung cancer	3.86e-06	8.81e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGFR—lung cancer	3.78e-06	8.61e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—lung cancer	3.75e-06	8.56e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—POMC—lung cancer	3.75e-06	8.55e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CREBBP—lung cancer	3.65e-06	8.33e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT1—lung cancer	3.62e-06	8.24e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HRAS—lung cancer	3.59e-06	8.18e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KRAS—lung cancer	3.57e-06	8.14e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CD—lung cancer	3.46e-06	7.89e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—lung cancer	3.44e-06	7.83e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALB—lung cancer	3.42e-06	7.79e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CA—lung cancer	3.28e-06	7.48e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKT1—lung cancer	3.28e-06	7.47e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—lung cancer	3.17e-06	7.23e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT1—lung cancer	3.17e-06	7.23e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HRAS—lung cancer	3.03e-06	6.92e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CB—lung cancer	3.02e-06	6.88e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—lung cancer	2.99e-06	6.82e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—lung cancer	2.9e-06	6.62e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT1—lung cancer	2.68e-06	6.11e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTEN—lung cancer	2.61e-06	5.95e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—EP300—lung cancer	2.49e-06	5.67e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CA—lung cancer	1.84e-06	4.19e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKT1—lung cancer	1.5e-06	3.43e-05	CbGpPWpGaD
